Suppr超能文献

Child C 级肝硬化患者肝细胞癌的预后因素及治疗效果

Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis.

作者信息

Nouso K, Ito Ym, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, Yamamoto K

机构信息

Department of Internal Medicine, Hiroshima City Hospital, Hiroshima, Japan.

出版信息

Br J Cancer. 2008 Apr 8;98(7):1161-5. doi: 10.1038/sj.bjc.6604282. Epub 2008 Mar 18.

Abstract

The aim of this study is to elucidate the prognostic factors and the treatment effect on survival in hepatocellular carcinoma (HCC) patients with Child C cirrhosis. Out of 3330 newly discovered HCC patients, 157 consecutive HCC individuals with Child C cirrhosis were enrolled. The prognostic factors were examined by Cox proportional hazards regression analysis and their survival was compared by propensity score-matched analysis. Multivariate analysis revealed that high serum bilirubin (>3 mg dl(-1)), the presence of uncontrollable ascites, and a high platelet count (>8 x 10(4) mm(-3)), so-called background liver factors, as well as multiple tumours, large tumours (>3 cm), high alpha-fetoprotein (>400 ng ml(-1)), and the presence of portal vein thrombus, so-called tumour factors, were factors of poor prognosis. While transcatheter arterial chemoembolisation (TACE) was a factor of good prognosis (relative risk=0.50, 95%CI=0.27-0.89, P=0.019), local ablation therapy and transcatheter arterial chemoinfusion (TAI) were not significant prognostic factors. The survival of patients who received TACE was superior to matched patients without active treatment (P=0.009); however, we did not observe survival benefit after local ablation therapy or TAI. These results suggested that tumour factors as well as background liver factors are prognostic factors of HCC even in patients with Child C cirrhosis, and selective use of TACE in these patients provides survival benefit.

摘要

本研究旨在阐明Child C级肝硬化的肝细胞癌(HCC)患者的预后因素及生存治疗效果。在3330例新发现的HCC患者中,连续纳入了157例Child C级肝硬化的HCC患者。通过Cox比例风险回归分析检查预后因素,并通过倾向评分匹配分析比较他们的生存情况。多变量分析显示,高血清胆红素(>3 mg dl(-1))、存在无法控制的腹水和高血小板计数(>8 x 10(4) mm(-3)),即所谓的背景肝因素,以及多发肿瘤、大肿瘤(>3 cm)、高甲胎蛋白(>400 ng ml(-1))和门静脉血栓形成,即所谓的肿瘤因素,均为预后不良的因素。虽然经动脉化疗栓塞术(TACE)是预后良好的因素(相对风险=0.50,95%CI=0.27-0.89,P=0.019),但局部消融治疗和经动脉化疗灌注术(TAI)不是显著的预后因素。接受TACE治疗的患者的生存情况优于未接受积极治疗的匹配患者(P=0.009);然而,我们未观察到局部消融治疗或TAI后的生存获益。这些结果表明,即使在Child C级肝硬化患者中,肿瘤因素以及背景肝因素也是HCC的预后因素,并且在这些患者中选择性使用TACE可提供生存获益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验